Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma.

Yunchao Li,Chunhua Zhao,Zhibin Yu,Jiarui Chen,Xiaoling She,Peiyao Li,Changhong Liu,Yan Zhang,Jianbo Feng,Haijuan Fu,Bing Wang,Lei Kuang,Lei Li,Guohua Lv,Minghua Wu
DOI: https://doi.org/10.18632/oncotarget.11861
2016-01-01
Oncotarget
Abstract:Osteosarcoma (OS) is the most common primary bone malignancy with a poor prognosis for all races and both sexes. In this study, we found that miR-381 is a positive prognosis factor for OS patients that OS patients with a low expression of miR-381 had a longer survival time after surgical intervention, and miR-381 expression promotes MG-63 cell proliferation and cell invasion ability. Our results also showed a strong negative correlation between the expression of miR-381 and LRRC4 (brain relative specific expression gene) in OS tissues. This demonstrated that LRRC4 is a direct target gene of miR-381, and suppressing the expression of miR-381 increases the sensitivity of OS cells to chemotherapeutic drugs through the LRRC4-mediated mTOR pathway. In summary, miR-381 is an important biomarker in directing therapeutic intervention and predicting prognosis in OS patients.
What problem does this paper attempt to address?